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Radioimmunotherapy (RIT) is a therapeutic modality that allows delivering of ionizing radiation directly to targeted
cancer cells. Conventional RIT uses β-emitting radioisotopes, but recently, a growing interest has emerged for
the clinical development of α particles. α emitters are ideal for killing isolated or small clusters of tumor cells,
thanks to their specific characteristics (high linear energy transfer and short path in the tissue), and their effect
is less dependent on dose rate, tissue oxygenation, or cell cycle status than γ and X rays. Several studies have
been performed to describe α emitter radiobiology and cell death mechanisms induced after α irradiation. But so
far, no investigation has been undertaken to analyze the impact of α particles on the immune system, when several
studies have shown that external irradiation, using γ and X rays, can foster an antitumor immune response.
Therefore, we decided to evaluate the immunogenicity of murine adenocarcinoma MC-38 after bismuth-213 (213Bi)
irradiation using a vaccination approach. In vivo studies performed in immunocompetent C57Bl/6 mice induced a
protective antitumor response that is mediated by tumor-specific T cells. The molecular mechanisms potentially
involved in the activation of adaptative immunity were also investigated by in vitro studies. We observed that
213Bi-treated MC-38 cells release “danger signals” and activate dendritic cells. Our results demonstrate that α
irradiation can stimulate adaptive immunity, elicits an efficient antitumor protection, and therefore is an immu-
nogenic cell death inducer, which provides an attractive complement to its direct cytolytic effect on tumor cells.
Neoplasia (2014) 16, 319–328yte; DAMP, danger-associated molecular pattern; RIT, radioimmunotherapy
niversité de Nantes, CRCNA–UMR 892 INSERM, 6299 CNRS, 8 quai Moncousu, BP
the absence of any commercial or financial relationships that could be construed as a
f methodology—J.-B.G. and J.G. Acquisition of data—J.-B.G., J.M., S.G., C.M., A.F.-C.,
.Writing, review, and/or revision of themanuscript—J.-B.G., J.M., S.G., Y.G.,M.C., F.D.,
from the Pays de la Loire Council “Nucléaire pour la Santé” (NucSan). J.-B.G. and J.M.
.M. and F.B. are supported by the European Commission.
320 Antitumor Immunity and α Irradiation Gorin et al. Neoplasia Vol. 16, No. 4, 2014Introduction
Radiotherapy is one of the most common treatments of cancer and
has been efficiently used for decades. Ionizing radiation is used to
eradicate cancer cells through direct cytotoxicity potentially associated
with a bystander and other nontargeted effects [1–3]. Numerous
radiotherapy modalities have been developed, among which radio-
immunotherapy (RIT) is one of the most promising for the treatment
of disseminated cancers. RIT is an internal form of radiotherapy using
radiolabeled vectors to target antigens expressed on tumor cells [4].
This therapeutic approach has significantly progressed for the past
20 years with the development of new vectors, improvement of
labeling efficiencies, and availability of new radionuclides [5]. Among
those, α particles are very attractive for clinical development. Indeed,
the physical and biologic characteristics of those radioisotopes ap-
pear to be especially suited for targeting isolated cancer cells, small
clusters of tumor cells, or micrometastasis. α particles exhibit a high
linear energy transfer (~100 keV/μm) with an energy comprised in
between 5 and 9 MeV and a short path of 50 to 90 μm in the tissues.
Like other high linear energy transfer particles, α emitters induce
more DNA double-strand breaks than γ or X rays and provoke a cell
cycle arrest in the G2 phase that is more marked than with γ rays
[6,7]. It has been shown that irradiation of the nucleus with a few
α particles is sufficient to result in cell death [8] and only a few
dozens are needed when the membrane is targeted, whereas several
thousands of β emitters are required for the same effect [9]. Fur-
thermore, radiobiologic effects associated to α radionuclides are
advantageously less sensitive to dose rate, hypoxia, and cell cycle
distribution than β particles or γ rays [10]. Other aspects of α emitter
radiobiology have been less investigated. For instance, few studies
have analyzed cell death mechanisms, and those are sometimes
conflicting. Some groups showed that cells undergo apoptosis
following exposure to α particles [11,12] when others observed cell
death independent from apoptosis [13,14].
However, it has become increasingly clear that direct cytotoxicity
is not the only factor accounting for tumor destruction by ionizing
radiation in vivo. Indirect effects such as radiation-induced biologic
bystander effects significantly contribute to the effectiveness of irra-
diation [15], and numerous studies have demonstrated that external
treatment with γ and X rays can have a beneficial effect at distance
from the field of irradiation. This phenomenon is called abscopal
effect and has been shown to be mediated by the immune system
[16,17]. Accumulating evidence also shows that the immune
response may play an important role in patient response to radiation
[18]. Several mechanisms have been proposed to explain the im-
plementation of such an antitumor response after radiotherapy.
First, irradiation induces local inflammation of tumor sites and
microenvironment that favors the recruitment of immune cells, in
particular dendritic cells (DCs). Additionally, DCs are capable of
cross-presenting antigens from the tumor cells killed by irradiation
to stimulate a specific T cell response. Finally, the stress induced by
ionizing radiation provides the immune system with signals, called
“danger signals” or danger-associated molecular patterns (DAMPs),
needed for activation of antigen-presenting cells (APCs) such as DCs
[19]. These results, obtained in animals after external irradiation,
underline the importance of studying the impact of ionizing radia-
tion on immune cells and their potential in stimulating an immune
response that could complement the direct effect of irradiation and
establish a long-term antitumor response. Nevertheless, the influence
of α radiation on immunity has not been investigated so far.Therefore, our study aims to investigate the potential of bismuth-213
(213Bi), an α emitter generated from an actinium-225/213Bi generator,
in stimulating immune cells. We used MC-38 tumor cells, a murine
adenocarcinoma, which has been reported to be weakly immunogenic
and a good model for immunotherapy studies [20,21]. To study the
impact of the radioelement on the tumor cells only, without irradiating
the microenvironment and without any vectorization that could also act
on the tumor cells, we chose a vaccination approach in immunocom-
petent C57Bl/6 mice. Additional in vitro studies were conducted to
investigate the molecular mechanisms involved after MC-38 irradiation
on the activation of adaptative immunity, in particular DCs and T cells,
and the establishment of long-termprotection toward tumor cells.Here,
we report for the first time that tumor cells irradiated with an α particle
emitter lead to the development of a long-lasting antitumor immune
response mediated by specific T cells in vivo. We also demonstrate
in vitro that irradiation of MC-38 cells with 213Bi induces the release of
DAMPs [i.e., heat shock protein 70 (Hsp70) and homeostatic group
box protein 1 (HMGB1)] and triggers the activation of DCs.Materials and Methods
Cell Culture
MC-38 murine colon carcinoma (established by Rosenberg's
laboratory, National Cancer Institute, Bethesda, MD [20] and kindly
provided by Dr Pèlegrin, CRLC Val d'Aurelle-Paul Lamarque,
Montpellier, France) and B16-F10 murine melanoma (ATCC®: CRL-
6475, LGC Standards, Molsheim, France) were maintained in
Dulbecco's modified Eagle's medium (Gibco) supplemented with
10% fetal calf serum (PAA Laboratories, Velizy-Villacoublay, France),
2 mM glutamine (Invitrogen, Cergy Pontoise, France), 100 U/ml
penicillin, and 100 μg/ml streptomycin (Gibco) at 37°C and 5%CO2.
213Bi Irradiation
Cyclohexyl diethylene triamine penta-acetic acid (Macrocyclics,
Dallas, Texas) was conjugated to BSA as previously described [22] and
controlled by indium labeling. For labeling with 213Bi, conjugated
BSA was incubated with 213Bi eluted from a actinium-225/213Bi
generator (Institute for Transuranium Elements, Karlsruhe, Germany)
for 10 minutes at 37°C in 0.6 M sodium acetate (pH 5.3) and 0.01%
ascorbic acid. The resulting 213Bi-BSA conjugate was purified from
unbound 213Bi by size exclusion chromatography using a PD-10 column
(GEHealthcare, Velizy-Villacoublay, France). Radiochemical purity was
N95%, as determined by Instant Thin Layer Chromatography - Silica
Gel using 0.1Mcitrate buffer (pH4.5). A solution containing 213Bi-BSA
diluted in culture media was then added to the cells at a final activity of
2.22 MBq/ml 213Bi for vaccination and 0.74 MBq/ml for in vitro
studies. 213Bi-BSA was removed after 6 hours, by centrifugation and
washing the cells with fresh medium, when used for vaccination.
Annexin V and 4′, 6-Diamidino-2-phenylindol (DAPI) Staining
Staining was performed according to manufacturer's instructions
(Annexin V-APC Apoptosis detection kit, BD, Le Pont de Claix,
France). Briefly, cells were washed in phosphate-buffered saline (PBS)
and resuspended at 1 × 106 cells per milliliter in 1× Annexin binding
buffer [10 mMHepes/NaOH (pH 7.4), 140 mMNaCl, and 2.5 mM
CaCl2]. A population of 10
5 cells was then stained with 5 μl of Annexin
V-APC and/or 1 μl of DAPI for 2 minutes at room temperature in the
dark. At least 10,000 events were analyzed using BD FACSCanto II
flow cytometer and FlowJo software (TreeStar, Ashland, OR).
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Caspase-3 assay was performed using the PE Active Caspase-3
Apoptosis kit (BD Pharmingen, Le Pont de Claix, France) according to
the manufacturer's instructions. Briefly, cells were washed once in PBS
and resuspended in BD Cytofix/Cytoperm on ice for 20 minutes. After
two washes in BD Perm/Wash, cells were stained with the PE
antiactive caspase-3 antibody for 30 minutes at room temperature. At
least 50,000 events were analyzed using BD FACSCalibur flow
cytometer and FlowJo software.
Mice and Vaccination
Wild-type C57Bl/6 (H-2b) mice aged between 11 and 17 weeks and
14-week-old nudemice (RjOrl:NMRI-Foxn1nu/Foxn1nu; Janvier Labs,
Le Genest-Saint-Isle, France) were immunized with 3 × 106 irradiated
MC-38 injected subcutaneously in the left flank. The injection was
performed after 6 hours of incubation with the radioconjugate to allow
for complete radioactive decay of 213Bi before injection, thus limiting
irradiation of the mice. Seven days later, the mice were challenged with
2 × 105 live MC-38 s.c. in the right flank. Tumor progression was then
assessed regularly using calipers, and mice were killed when tumor
volume reached 2500 mm3 or when signs of tumor necrosis were
observed. Experiments performed in this study were approved by the
local veterinary committee (License No. CEEA.2013.2).
T Cell Preparation
Mice were killed 5 days after their last injection, and axillary,
inguinal, popliteal, and mesenteric lymph nodes were recovered.
T cells were then purified using Pan T Cell Isolation Kit II (Miltenyi
Biotec, Bergish Gladbach, Germany) and stimulated in vitro with
5 μg/ml anti-CD3ε (clone 145-2C11; eBioscience) and 2 μg/ml
anti-CD28 (clone 37.51; eBioscience). T cells were then cultured until
they went back to a resting state (no proliferation).
Cytotoxicity Assay
Cytotoxic activity was tested using a standard 51Cr release assay.
Briefly, MC-38 or B16-F10 autologous tumor cell lines were used as a
target and labeled with 2.77 MBq of Na2
51CrO4 for 1 hour at 37°C,
washed five times, and then plated onto 96-well U-bottom plates.
Effector-to-target ratios (E:T ratios) were 20:1, 10:1, 5:1, and 2.5:1.
After 16 hours of incubation at 37°C, 25 μl of supernatant from each
well was removed, mixed with 100 μl of Betaplate Scint
(PerkinElmer, Waltham, MA), and read using 1450 MicroBeta
Plus counter (Wallac, Gaithersburg, MD). Each test was performed
in triplicate. Results were expressed as a percentage of lysis according
to the following formula: (experimental release − spontaneous
release)/(maximal release − spontaneous release) × 100, where
experimental release represents mean cpm release from target cells
in the presence of effector cells, spontaneous release represents that
from targets incubated without effectors, and maximum release
represents that from target cells incubated with 1% triton.
DAMP Detection in Culture Media
DAMP release in cell culture was assessed using ELISA directed against
Hsp70 (R&D Systems, Abingdon, UK) and HMGB1 (IBL Interna-
tional, Hamburg, Germany) following the manufacturers' protocols.
Bone Marrow-Derived Dendritic Cell Production
Bone marrow cells were flushed with RPMI medium from C57Bl/
6 thighbones and filtered through a 70-μm cell strainer. Adherent
cells were cultured in RPMI 1640 (Gibco) supplemented with 10%fetal calf serum (PAA Laboratories), 2 mM glutamine (Gibco),
100 U/ml penicillin, 100 μg/ml streptomycin (Gibco), 100 μM
2-mercaptoethanol (Carl Roth, Karlsruhe, Germany), minimum
essential medium nonessential amino acids (Gibco), and murine GM-
CSF (purified from the supernatant of a transgenic GM-CSF
(Granulocyte macrophage colony-stimulating factor)–producing cell
line [23]) to induce bone marrow-derived dendritic cell (BMDC)
differentiation. On day 3, fresh medium was added; on days 6 and 8,
half of the medium was removed and replaced by fresh medium; and
BMDCs were used on day 10.
Coculture Assays
For BMDC coculture assay with tumor cells, 1 × 106 murine
BMDCs were plated onto six-well dishes with 5 × 106 MC-38 and
incubated 24 hours at 37°C. Maturation was then analyzed by
immunofluorescence phenotyping. For BMDC maturation with
tumor cell supernatant, 1 ml of tumor cell supernatant was added to
1 × 106 BMDCs and plated onto 12-well dishes. BMDC phenotype
was analyzed by immunofluorescence after 24 hours of incubation.
Immunofluorescence Analysis
Cells were washed once in PBS-BSA (0.1%) and then stained for
1 hour at 4°C with primary antibody. When secondary antibody was
needed, cells were washed three times in PBS-BSA (0.1%) before
incubation with secondary antibody. After staining, cells were washed
twice in PBS-BSA (0.1%) and once in PBS before acquisition in flow
cytometer. The following antibodies and their respective control iso-
types were used in this study: Alexa 647 anti-mouse CD11c (N418;
eBioscience), fluorescein isothiocyanate (FITC) anti-mouse CD11b
(M1/70; BD), FITC anti-mouse CD34 (RAM34; BD), FITC anti-
mouse CD80 (16-10A1; BD), APC anti-mouse CD86 (GL1; BD),
and APC anti-mouse CD40 (1C10; eBioscience). Immunofluo-
rescence analyses were performed using BD FACSCalibur flow cyto-
meter and analyzed with FlowJo software.
Data Analysis
Data are expressed as the means ± SD. Survival data were analyzed
using the log-rank test and Kaplan-Meier method. Comparisons of
continuous variables were done using nonparametric Mann-Whitney
tests or two-way analysis of variance (GraphPad Prism version 5.0, La
Jolla, CA).P values of less than or equal to .05 are considered significant.
Results
Vaccination of Mice with Irradiated Cells Induces a
Protective Antitumor Response In Vivo
To determine whether α-irradiated cells could foster an antitumor
response in vivo, we conducted vaccination studies on syngeneic
C57Bl/6 mice. Mice were vaccinated 7 days before MC-38 engraft-
ment by s.c. injection of 3 × 106 213Bi-treated MC-38 (without
any adjuvant), in the left flank. Irradiation was performed using
213Bi-BSA conjugates; however, BSA does not target tumor cells.
This approach was chosen to avoid any interaction that specific
vectors such as antibodies could have on tumor cells as well as with
the immune response. This way, we only studied the effects of the
radioelement and not the effects of the vector. Cells were incubated
for 6 hours with the radioconjugate and then washed with fresh
medium before injection. This allowed for complete radioactive decay
and elimination of 213Bi, thus limiting irradiation of the mice. At
the time of injection, viability of 213Bi-treated MC-38 was controlled
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activation. Both analyses showed that irradiation had no impact yet
on death mechanisms because percentages of the live cells were
identical in 213Bi-treated MC-38 and nonirradiated MC-38.
However, irradiation induced N95% cell killing on the long term,
as determined by clonogenic assays (data not shown). On day 0,
mice were engrafted with 2 × 105 live MC-38 injected s.c. in the
opposite flank to make sure that any response observed would have
to be systemic and not just due to local control. Among
nonvaccinated controls, 21 of the 25 mice rapidly developed a
tumor and reached end-point value within 40 days (Figure 1A).
However, only 3 of 25 vaccinated mice developed a tumor
(Figure 1B). Median survival was 37 days for controls and was not
reached for the vaccinated group after more than 100 days of
monitoring. Overall survival at 73 days after live tumor cell
engraftment was 88% for the vaccinated mice compared to 16% inFigure 1. Tumor cells irradiated with 213Bi give rise to antitumor pr
(A) and immunized mice (B) after MC-38 engraftment. Volume was
analysis of mice immunized with 213Bi-treated cells (square) versus c
live MC-38. Median survival was 37 days for controls and was not rea
test was extremely significant (P b .0001). (D) Tumor-free fraction ocontrol group (Figure 1C). This demonstrates that 213Bi-irradiated
tumor cells are highly immunogenic and can elicit a strong antitumor
response in vivo.
To follow the induced immune response, 17 of the 22 mice that
rejected MC-38 on live tumor cell injection were challenged a second
time on day 73. Remarkably, 100% of the animals showed full
protection by rejecting that second engraftment (Figure 1D). This
result demonstrates that the antitumor response was long lasting,
hence most likely driven by the adaptive immunity.
An additional group of 10 mice was included in the study,
receiving the vaccination but not the first challenge with live MC-38
cells on day 0. Vaccinated mice did not grow any tumor, showing that
irradiated cells could not participate in tumor growth (Figure 2A).
Those mice were then challenged 84 days after vaccination.
Interestingly, among that group, 90% of the animals rejected the
live tumor cell graft (Figure 2B). Those data confirm that α-irradiatedotection in vivo. (A and B) Tumor volume progression for control
calculated as (length × width × height × π)/6. (C) Kaplan-Meier
ontrol C57Bl/6 (circles) after subcutaneous challenge with 2 × 105
ched for the immunized group. P value determined by the log-rank
f mice after a second challenge with live MC38. P b .0001.
Figure 2. Tumor cells irradiated with 213Bi do not give rise to tumors and allow for long-term antitumor protection. (A and B) Tumor volume
progression for vaccinated mice (A), which did not receive live MC-38 engraftment before day 84. Kaplan-Meier analysis of mice
immunized with 213Bi-treated cells (triangles) versus control C57Bl/6 (circles) after subcutaneous challenge with 2 × 105 live MC-38.
P value determined by the log-rank test was highly significant (P b .0001).
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response has been elicited without any boost or adjuvant.
The Antitumor Response Induced In Vivo Is
T Cell Mediated
To investigate the cell subsets involved in the antitumor response
induced through α-irradiated MC-38, we performed vaccination
studies on immunodeficient athymic mice (nude) (n = 5), which lack
T cells. We observed no protection against tumor challenge after
vaccination. Kinetics of tumor development appeared very similar in all
the mice (Figure 3, A and B), and median survival was 13 days for both
the control and vaccinated groups (Figure 3C), indicating that T cells
are essential for the antitumor effect obtained through vaccination.Figure 3. Immunization with α-irradiated MC38 fails in nude mice.
immunized nude mice (n = 5) (B) after MC38 engraftment. (C) Kaplan
versus control nudemice (circles) after subcutaneous challenge with 2
and immunized groups. P = .5716.Cytotoxic T lymphocytes (CTL) are known as potent effectors in
anticancer treatments; therefore, we investigated the presence of CTL
specifically targeted toward MC-38 following immunization. T cells
were purified from the mice lymph nodes and tested through a con-
ventional chromium release assay (Figure 4). T cells from naïve mice
exhibited a weak cytotoxic efficiency towardMC-38 cells, varying from
6.7% to 11.7% independently from the E:T ratio (Figure 4A). Simi-
larly, cytotoxic efficiency toward another syngeneic, but nonrelated,
tumor cell line (B16-F10 melanoma) was weak and did not exceed
3.4 ± 3.8% at any E:T ratio tested (Figure 4A). After vaccination with
213Bi-irradiated MC-38 and subsequent tumor challenge a week later,
a significant increase of cytotoxic efficiency toward MC-38 was ob-
served, ranging from 40.0 ± 9.7% for an E:T ratio of 2.5:1 to 74.0 ±(A and B) Tumor volume progression for control (n = 5) (A) and
-Meier analysis of mice immunized with 213Bi-treated cells (square)
× 105 live MC-38. Median survival was 13 days for both the control
Figure 4. Antitumor response is dependent on cytotoxic T cells. (A and B) 51Cr release assay against MC-38 or the irrelevant cell line
B16-F10 was performed on T cells purified from naïve mice (A) or mice that had been immunized with 213Bi-treated MC-38 and
subsequently challenged with live MC-38 (B). Assays were performed at different E:T ratios ; data points represent means ± SD of
triplicate measurements for three naïve mice (A) and four vaccinated + challenged mice (B). (C) Scatterplot of mean percentage of T cell
cytotoxicity against MC-38 at the E:T ratio of 10:1 for different groups of mice. In parentheses, number of mice in each group. P b .05
between naïve mice and mice that have been immunized and challenged. P value was determined by nonparametric Mann-Whitney
test. Mean cytotoxicity was 7.87% for naïve mice, 19.15% for challenged mice, 16.2% for vaccinated mice, and 55.85% for
vaccinated + challenged mice.
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antitumor T cell response had been raised. On the contrary, cytotoxic
efficiency toward B16-F10 melanoma did not increase and was only
1.0 ± 1.8% at the highest E:T ratio, indicating that the T cell response
was specific to MC-38. Comparison of naïve, challenged, vaccinated,
and vaccinated + challenged mice showed that CTL activity was only
significantly increased in vaccinated + challenged mice at the E:T ratio
of 10:1 with 55.9% cytotoxicity compared to 7.9% in naïve animals
(Figure 4C). Together with our data on the vaccination of nude mice,
these results suggest that CTL is the main effector of the antitumor
response raised after vaccination with α-irradiated tumor cells.
Tumor Cells Treated with 213Bi Activate DCs In Vitro
To further explore the mechanisms supporting the antitumor
immune response to α particles, we analyzed the DC phenotype after
in vitro irradiation of MC-38 cells. DCs express costimulatory
molecules such as CD40, CD80, and CD86 on their cell surface,
which are needed for activation of naïve T cells. Activation of
immature DCs results in increased expression of those costimulatory
molecules. Immature BMDCs derived from syngeneic C57Bl/6 mice
have been incubated for 48 hours with conditioned media from
control or 213Bi -treated MC-38. The media of irradiated tumor cells
elicited a significant increase of 32% in CD40 expression [ratio of
fluorescence intensity (RFI) increased from 4.5 to 5.9] and 44.8%
in CD86 expression (22.7 to 32.6) and a slight increase, however
not significant, of 4.4% in CD80 expression (3.3 to 3.4) on BMDCs
(Figure 5, A–C). Besides, we observed that BMDCs aggregated inclumps (Figure 5, D and E) when incubated in culture inserts with
irradiated MC-38, which is a phenotypic characteristic of DC
activation [24]. No activation was observed when immature BMDCs
were exposed to irradiated culture medium only (data not shown).
These results suggest that 213Bi induces the release of soluble agents
from MC-38 capable of activating DCs in vitro.
213Bi Irradiation Causes Release of DAMPs from
MC-38 Cells
Then, we tested the conditioned media of 213Bi-treated MC-38
for the presence of DAMPs. DAMPs such as Hsp70 or HMGB1 are
self-molecules normally expressed intracellularly, which can be re-
leased in the extracellular space upon cell stress or damage as a danger
signal to the immune system [25,26]. Those molecules are known to
activate DCs and have been implicated in the establishment of
efficient antitumor response [27]. ELISA on MC-38 conditioned
media showed a significant increase of HMGB1 and Hsp70 levels
following 213Bi irradiation (Figure 6). This increase in both DAMP
concentrations started 24 and 48 hours post-irradiation for Hsp70
and HMGB1, respectively. Altogether, these data show that 213Bi
induces the release of DAMPs from irradiated tumor cells, which may
contribute to the antitumor response by activating DCs.
Discussion
Radiotherapy is traditionally used for its cytotoxic effect on cancer
cells. There is however growing evidence showing that direct cyto-
toxicity is not the only process through which radiation may
Figure 5. 213Bi-irradiatedMC-38 elicit DCmaturation. (A–C) Triplicate analysis of RFI for CD40 (A), CD80 (B), and CD86 (C). RFI is calculated
as geometric mean of fluorescence intensity of the specific antibody divided by that of the control isotype. (D and E) Snapshot of BMDC
after 24 hours in culture with 5 × 106 control MC38 (D) or 5 × 106 irradiated MC-38 (E). *P ≤ .05 determined using Mann-Whitney
nonparametric test.
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irradiated tumor cells are highly immunogenic and can elicit a strong
antitumor response in vivo that protects immunocompetent hosts
against further tumor challenge with the same tumor. Indeed, 88% of
the vaccinated animals survived to the injection of live MC-38 tumor
cells. α particles therefore fulfill the first requirement defined byFigure 6. DAMP release after irradiation. (A and B) Evolution of Hsp70
conditioned media after irradiation with 213Bi (squares) and on co
measurements. ***P b .001 as determined by two-way analysis of va
independent experiments.Kroemer's group to be defined as an immunogenic cell death inducer
[28]. Our results show that irradiation of tumor cells with 213Bi can
lead to the elimination of other tumor cells in a distant site, even long
after the irradiation. The protective effect of vaccination was indeed
long lasting (at least 2 months) and must therefore involve memory
cells. Strikingly, this immune protection was observed in all the(A) and HMGB1 (B) concentrations determined by ELISA on MC-38
ntrols (circles). Data points represent means ± SD of triplicate
riance and Bonferonni posttests. Results are representative of two
326 Antitumor Immunity and α Irradiation Gorin et al. Neoplasia Vol. 16, No. 4, 2014animals subjected to a second challenge with live MC-38 cells. The
response was T cell mediated as demonstrated by the presence of
specific cytotoxic T cells and by the lack of protection in nude mice.
This kind of specific, systemic, and long-lasting response would be
highly desirable for anticancer therapy because it should help in
eliminating distant metastases and preventing relapse. However, T
cells may not be the only cells needed for an efficient antitumor effect.
Nude mice have functional Natural Killer (NK) and B cells that could
participate in the immune response. Further experiments will help to
clarify the role of each immune subset in the antitumor response.
Interestingly, tumors grew much faster in nude mice with a median
survival of 13 versus 37 days in C57Bl/6 immunocompetent mice.
Moreover, 4 of the 25 challenged mice did not develop a tumor, and
the rest of the challenged animals showed a slight increase in
cytotoxicity against MC-38 compared to naïve mice (however not
significant). These data suggest that live tumor cells exhibit some level
of immunogenicity, probably related to the fact that the MC-38 cells
we used express high levels of major histocompatibility complex class
I molecules (data not shown). Although this immune response slows
down tumor growth to some extent, it is not sufficient for tumor
control in 84% of the animals. This could mean two things: either
tumor cells multiply too quickly for the immune response to cope
with it, or the immune system sees the tumor as harmless self and
represses the initial antitumor response. In both cases, α radiation
delivered through RIT would be of great therapeutic interest. Indeed,
the high cytotoxicity of α particles could reduce tumor load, and at
the same time, α-irradiated tumor cells could activate the immune
response and tip the balance toward an effective antitumor response.
Additional studies using less immunogenic tumors will however be
required to determine whether α radiation would be as efficient in
triggering an immune response in such settings.
To depict the mechanisms that could contribute to activation of
T cells in vivo, we pursued in vitro studies on DCs. Their role in
anticancer immunity is indeed crucial. When activated with the
adequate stimuli, DCs can cross-present tumor-derived antigens to
T cells and secrete stimulatory cytokines, which will lead to the
establishment of an effective cell-mediated antitumor response. Con-
versely, if not properly activated, DCs may promote tolerance and T cell
unresponsiveness. In fact, in amajority of cancer, the antitumor response
is repressed by the host's immune regulatory cells [29]. Here, we exposed
immature BMDCs to conditionedmedia from irradiatedMC-38 tumor
cells and observed significant changes in both DC morphology and
expression profile of several DC activation markers, demonstrating the
potency of α-irradiated tumor cells in triggering immune activation.
To further investigate the molecular processes that could
contribute to the activation of DCs in vitro, we conducted ELISA
tests on the conditioned media of α-irradiated tumor cells to detect
the presence of well-characterized DAMPs [30]. In vivo, as irradiated
tumor cells were washed in PBS before vaccination, the molecules
involved in immune cells activation cannot be irradiated molecules
from the culture medium and have to be secreted by the tumor cells
after exposure to 213Bi. Besides, irradiated culture medium alone did
not induce DC activation. We showed that 213Bi causes the release of
Hsp70 and HMGB1 from MC-38 cells. Such molecules, which are
normally endogenous, get released in the extracellular environment
after a stress or nonphysiological cell death and can activate immune
cells [26,31]. HSP are chaperone proteins capable of binding
numerous peptides. The HSP-peptide complexes released from
dying cells can be taken up by APC through the common receptorCD91 to allow for antigen processing and re-presentation to T cells
[32]. HMGB1 is a ubiquitous nonhistone nuclear factor that mediates
inflammation and immune responses when released from dying cells
[33]. HMGB1 production in patients with cancer has conversely been
reported in associationwith both good [34] and poor prognoses [35,36].
HMGB1 has also been involved in numerous processes facilitating
tumor progression, such as proliferation [37], metastasis [38,39],
angiogenesis [40], and chronic inflammation [41]. The differential
activity of HMGB1 is related to the balance of its different redox states
(i.e., all-thiol, disulfide, and sulfonated) that are produced in the
extracellular environment [42]. In the case of radiotherapy, a rapid and
local increase of HMGB1 might act differently on the immune system
than a chronic systemic secretion.Notably,HMGB1 has been shown to
be mandatory for cross-presentation of antigen derived from dying
tumor cells to T cells after radiotherapy, leading to efficient antitumor
immune response [43]. Further studies will be required to determine the
importance of these DAMPs in the establishment of an immune
response in our settings. Using larger screening techniques (i.e., mass
spectrometry), it will also be important to identify other species
produced after irradiation contributing to such bystander phenomena.
All these data underline the importance of the immune system in
response to radiotherapy of cancer. Nevertheless, most studies on RIT
efficacy are performed on xenograft models in immunodeficient mice.
Therefore, the participation of the immune system in response to
therapy is completely overseen. In the future, it will be of prime
importance to assess the response to cancer therapy in both immu-
nodeficient and immunocompetent models to take into account the
effect of radiation on both tumor cells and the immune environment.
In conclusion, the data presented here show that irradiation of tumor
cells with 213Bi induces the release ofDAMPs, promotesDC activation,
and leads to a systemic and long-lasting antitumor response. A few
studies have investigated the impact ofγ or β irradiation on the immune
system. It has been shown that external beam [44–46] or β emitters like
90Y [21] or 153Sm [47] could elicit effective antitumor response when
combined with vaccine or CTL transfer. Our study is in line with these
investigations and is the first to demonstrate that irradiation of tumors
using an α particle emitter can also lead to the establishment of an
efficient antitumor immune response in vivo. Even though the impact
of α irradiation on the immune response to cancer will have to be
further characterized, this study brings new insights on the mechanism
of action of α particles and further supports the interest in developing
the use of such emitters for cancer therapy.
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